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Dofetilide is an effective antiarrhythmic agent for conversion of atrial fibrillation and atrial
flutter as well as maintenance of sinus rhythm in appropriately selected patients. However,
as with other antiarrhythmic agents, proarrhythmia is a known adverse effect. The risk of
dofetilide induced torsade de pointes (Tdp) is low when used with strict dosing criteria
guided by renal function, QT interval and concomitant drug therapy. Benefit from dofeti-
lide use must be individualized and weighed against the side effects and the role of other
available treatment options. In this review, we discuss the underlying mechanism, risk
factors and precautionary measures to avoid dofetilide induced QT prolongation and
ventricular tachycardia/Tdp. We suggest a scheme for the management of QT prolonga-
tion, ventricular arrhythmia and Tdp as well.
Copyright ª 2013, Cardiological Society of India. All rights reserved.1. Background
The last decade has witnessed a large increase in the pre-
scription of antiarrhythmic drugs (AADs). The use of AADs is
predicted to rise due to the increasing incidence of atrial
fibrillation in our aging population. Several classes of AADs
have been shown to be effective in maintaining sinus rhythm.
However, most of these agents are also proarrhythmic and
many have been associated with severe and occasionally fatal
arrhythmias, most commonly presenting as torsade de pointes
(Tdp). Dofetilide is a class III antiarrhythmic drug which is
effective in maintaining sinus rhythm, but due to the signifi-
cant proarrhythmic risk initiation requires hospitalmonitoring.
We describe an update on the mechanism, risk factors, and
preventive measures associated with dofetilide induced
tachyarrhythmia, and propose an evidence based model on200, Cardiovascular Cen
(A. Jaiswal).
2013, Cardiological Sociemonitoring and management of ventricular arrhythmia/Tdp
associated with dofetilide.2. Dofetilide pharmacodynamics and
pharmacokinetics
Dofetilide is almost completely absorbed after oral adminis-
tration with a bioavailability of more than 90% and reaches
peak plasma concentration in approximately 2 h irrespective
of the dose. The steady-state plasma concentration is reached
by the third day of a twice-daily dosing regimen. Females tend
to have 14e22% higher plasma concentration thanmales even
after correcting for body weight and creatinine clearance.
After oral administration, plasma dofetilide has a linear
relationship with QTc interval. Dofetilide is mainly eliminatedter, New York Hospital Queens, Flushing, NY 11355, USA. Tel.: þ1
ty of India. All rights reserved.
Table 1 e Factors associated with increased risk of
developing drug-induced excessive QT prolongation and
Tdp.
1. EEG changes
a. Long QT interval
b. Increased QT dispersion
c. Increased interval from peak to end of T wave
d. T wave alternans
e. TeU waves
3. Electrolyte abnormalities
a. Hypokalemia
b. Hypomagnesemia
4. Female gender
5. Older age
6. HIV
7. Systolic dysfunction
8. Previous history of drug-induced long QT or Tdp
9. Close relatives with a history of drug-induced long QT
10. Recent cardioversion from atrial fibrillation
11. Decreased elimination/excretion of these drugs
Adapted with permission from.17
i n d i a n h e a r t j o u rn a l 6 6 ( 2 0 1 4 ) 6 4 0e6 4 8 641(approximately 80%) through the kidneys via passive
glomerular filtration and cationic tubular secretion. The
remainder is excreted in feces (<10%) or metabolized in liver,
predominantly by the cytochrome P4503A4 family, into inac-
tive metabolites. It exhibits first-order elimination kinetics
with a half-life of 8e10 h in patients with normal renal func-
tion. Patients with severe hepatic impairment have not been
studied.
Dofetilide is a pure Vaughan Williams class III antiar-
rhythmic drug. It acts by blocking the rapid component of the
cardiac delayed rectifier Kþ current (IKr), which is encoded by
human ether-a`-go-goerelated gene (hERG).1 This results in
prolongation of action potential duration and effective re-
fractory period. At the recommended doses, it causes selective
prolongation of the QT interval on the surface electrocardio-
gram (EKG) without any effect on PR, QRS, AH or HV intervals.2
This happens due to the lack of effect on slow component of
the delayed rectifier potassium current (Iks), the inward cur-
rent (IK1), any sodium channel (INa), calcium channel (ICa) or
beta-receptor.3 To sum up, dofetilide does not affect resting
membrane potential, maximum upstroke velocity of the ac-
tion potential (Vmax) and conduction velocity, and it has min-
imal effects upon myocardial contractility and systemic
hemodynamics. Dofetilide prolongs the refractory period in
the atria to a greater extent than in the ventricle. Dose for dose,
the increase in atrial effective refractory period is double that
of ventricular effective refractory period. Thismay account for
its greater effectiveness in treating atrial arrhythmias.Table 2 e Dofetilide drug interaction (common drugs).
 Cardiovascular drugs: Bepridil, Disopyramide, Dofetilide, Ibutilide, Pro
thiazide/Triamterene
 Antiobiotics/Antifungals/Antimalarials: Chloroquine, Halofantrine, Pen
Trimethoprim, alone or in combination with Sulfamethoxazole (CYP3A
 Antipsychotic drugs: Chlorpromazine, Haloperidol, Mesoridazine, Thio
sants like Amitriptyline or Desipramine
 Pain meds/sedatives/antiemetics: Droperidol, Levomethadyl, Methadon3. Clinical utility and adverse reactions
Dofetilide is one of the few antiarrhythmic agents which
appear to be safe in patients with myocardial infarction and
impaired left ventricular function (LVEF).4 In a study done on
small number of patients with paroxysmal atrial fibrillation
with preserved LVEF dofetilidewas found to be not effective in
maintenance of sinus rhythm.5
Dofetilide can cause serious ventricular arrhythmias, pri-
marily Tdp. Most commonly this is seen in patients due to
drug interaction or serum electrolyte abnormalities (Tables 1
and 2) which can cause higher serum concentration of dofe-
tilide. However, ventricular tachyarrhythmias have been re-
ported in patients on dofetilide in the absence of precipitating
factors.63.1. Torsade de pointes
Tdp is a polymorphic ventricular tachycardia associated with
QT interval prolongation which can degenerate into ventric-
ular fibrillation causing sudden cardiac death. A typical mode
of onset involves short-long-short sequence of RR intervals
(Fig. 2) which is also known as pause dependent phenome-
non.7 However, other mechanism of Tdp development has
been suggested in patients on beta blockers.7 So, Tdp normally
occurs under conditions in which repolarization reserve8 is
challenged beyond capacity, as in the long QT syndrome
(LQTS), or in congestive heart failure.9
Ventricular repolarization (Fig. 3) is achieved by rapid [IKr]
and slow [IKs] delayed rectifying potassium currents. When
these currents are reduced, repolarization is prolonged and
the QT interval increases. Both early and delayed depolarizing
currents, which may ensue during these prolonged repolari-
zation periods, may trigger a ventricular arrhythmia. Tdp is
classically associated with early-after depolarizations (EADs).
EADs are caused by inward calcium currents10 either due to
reopening of L-type calcium channels or sodium channels or
from current generated via augmented sodiumecalcium ex-
change. Ectopic beats occur when the amplitude of an EAD
reaches a critical threshold and occurs in a large enough re-
gion of the heart.11 Usually repolarization defects due to IKs
blockage are well tolerated and do not lead to Tdp. This can be
explained by potential compensation by other K currents,
mainly IKr. Agents which block IKr could induce QT interval
prolongation and Tdp. Therefore, conditions and drugs that
increase the number of L-type calcium channels in cardiac
fiber membranes may facilitate the induction of Tdp in pres-
ence of delayed repolarization.cainamide, Sotalol, and other antiarrhythmic agents, Hydrochloro-
tamidine Clarithromycin, Erythromycin, Sparfloxacin, Macrolides or
4 family), Ketoconazole
ridazine, Prochlorperazine or Trifluoperazine; Tricyclic antidepres-
e, Cimetidine
Fig. 1 e ECG showing prolonged QTc interval at 500 ms.
i n d i a n h e a r t j o u r n a l 6 6 ( 2 0 1 4 ) 6 4 0e6 4 8642Drugs are the most common cause of Tdp. Approximately
2e3% of all prescriptions are estimated to involvemedications
that may unintentionally cause acquired long QT syndrome
(LQTS).12 However, the incidence of drug-induced Tdp isFig. 2 e Tele strips showing precipitation of episodes of Tdp (Pa
classic features including a prolonged QT interval (Panel A), ini
sequence by a PVC that falls near the peak of the distorted T wa
cycles longer than subsequent cycles, and abrupt switching of
predominately negative complexes (Panel A & B).relatively low. This is likely a result of individual differences in
pharmacokinetics and pharmacogenomics. Other causes
include structural heart diseases including ischemia,
congestive heart failure, cardiomyopathy; bradycardia,nel A, B, C & D) during continuous telemonitoring with the
tiation of the arrhythmia after a short-long-short cycle
ve (Panel B & C), “warm-up” phenomenon with initial ReR
QRS morphology from predominately positive to
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Fig. 3 e Schematic representation of action potential of a ventricular myocyte. Rapid depolarization (phase 0) is caused by
opening of the fast sodium channels resulting a transient increase inward sodium current (INa). Phase 1 characterizes an
initial repolarization is a result of a short-lived, hyperpolarizing outward KD current (IKto) caused by the opening of a special
type of transient outward KD channel (Kto). Phase 2 or the plateau phase/slow repolarization represents delay in the
repolarization which caused by the inward calcium movement through long-lasting calcium channels (ICa L) that open up
when the membrane potential depolarizes to aboutL40 mV. Phase 3 or fast repolarization occurs when rectifier potassium
channels (IKr and IKs) open with simultaneous inactivation of the calcium channels. Phase 4 represents resting membrane
potential.
i n d i a n h e a r t j o u rn a l 6 6 ( 2 0 1 4 ) 6 4 0e6 4 8 643subarachnoid hemorrhage, human immunodeficiency virus
(HIV) infection and electrolyte abnormalities. Hypokalemia
is associated with decreased conduction velocity, short-
ening of the effective refractory period, prolongation of the
relative refractory period, increased automaticity and
EADs.13 Hypomagnesemia causes EADs due to its modu-
lating effect on L-type calcium channels. The proarrhythmic
effect of hypomagnesemia is increased in the presence of
hypokalemia and bradycardia. Because time for repolariza-
tion (the QT interval) is rate dependent, Tdp is more likely to
occur during slower heart rates.14 Hypocalcemia has been
associated with Tdp only in rare cases.15 In the absence of
these factors congenital QT syndrome (LQTS) could be a
culprit.
It has been proposed that subjects susceptible to drug-
induced Tdp may have underlying genetic mutations, which
would become apparent when exposed to a QT-prolonging
drug. Further, it has been speculated that some cases of
drug-induced LQTSmight be associated with silent mutations
and common polymorphism in genes responsible for the
congenital LQTS, such as KCNQ1 encoding slowly activating
delayed rectifier potassium currents (IKs). However, it re-
mains unclear why subclinical IKs dysfunction is a risk of
drug-LQTS.164. Risk prediction from electrocardiogram
(EKG) assessment
Surface EKG can predict Tdp risk inmajority of patients. There
are several EKG findings which may be associated with
increased risk (Fig. 1). In majority of cases, the development of
Tdp is inevitably accompanied by QT interval prolongation.
Tdp has also been seen in the absence of QT prolongation and
vice-versa. Usually, this is evident in each heartbeat, but
sometimes it occurs only in the beat or two before the Tdp.11
QT interval varies with heart rate and QTc describes a heart
rate corrected QT interval. QTc refers to the QT interval heart
rate correction, when not otherwise stated, generally refers to
the Bazett correction. QTc values greater than 450 ms for men
and 470 ms for women are usually considered prolonged QT
intervals.17 The Bazett correction tends to produce overlong
QTc values at faster heart rates, particularly above 85 beats
per minute.15 Alternative QTc calculation methods are avail-
able that adjust more appropriately at faster rates.
QT interval is measured from the beginning of the QRS
complex to the end of the T Wave. Although the onset of the
QRS complex is usually well defined, the end of the T wave is
often obscure, especially when T waves are of low amplitude
Table 3 e Published reports on Torsade de Pointes and sudden death.
Study Tdp rate Arrhythmic death Study Tdp rate Arrhythmic
death
Echt et al, 199533 1/18 (5.5%) Nagra et al, 200526 1, case report
Frost et al, 199734 0/65 (0%) Reiffel, 200535 1, case report
Ventricular tachycardia studies36 11/443 (2.4%) Aktas et al, 200737 4, case reports
DIAMOND CHF, 199922 25/762 (3.3%) Mykytsey et al, 20075 3/34
DIAMOND MI, 20004 7/749 (0.9%) Kolb et al, 20086 1, case report
SAFIRE-D, 200026 2/250 (0.8%) 1/250 (0.4%) Banchs et al, 200838 2/80 (2.5%)
Bianconi et al, 200039 4/48 (8%) Coleman et al, 200940 1/160 (0.6%)
DIAMOND AF, 200141 4/250 (1.6%) Shamiss et al, 200929 0/127
Mazur et al, 200142 15/87 (17%) Wells et al, 200943 2/30 (6.7%)
Prystowsky et al, 200344 2/69 (2.9%) 1/69 (1.4%) Pinter et al, 201145 0/18
Guanzon et al, 200446 0/107 Baquero et al, 201247 2/30 (6.7%) potentially?
Sun et al, 200448 7/105 (6.7%) Manocha et al, 201249 1/287 (0.3%)
Total Tdp
Sudden death
89/3719 (2.4%), and 7 case reports
2/3719 (0.05%)
i n d i a n h e a r t j o u r n a l 6 6 ( 2 0 1 4 ) 6 4 0e6 4 8644or T waveeU wave distortion is present. In a 12-lead ECG, the
leadwithwell defined Twave ending and amplitude of at least
2 mm should be used to measure QT interval. In cases where
the end of the T wave is difficult to determine (e.g., biphasic or
notched Twaves, T waves with superimposed Uwaves), it can
be determined by drawing a line from the peak of the T wave
following the steepest T-wave down slope. The intersection of
this line with the isoelectric baseline is considered the end of
the T wave.15
Calculation of QTc in the setting of atrial fibrillation could
be challenging due to beat to beat variability of the RR in-
tervals. One way to deal with the irregularity of the rhythm is
to identify the shortest and longest ReR intervals, calculate
the QTc for each, and mean of these QT intervals may repre-
sent QTc.15 Alternatively, a rhythm strip can be used deter-
mine whether, on average, the interval from R wave to the
peak (or nadir) of the T wave is more than 50% of the ReR
interval. A wide QRS complex will increase the total QT in-
terval. Such an increase of the QT interval due to a new con-
duction block should not be considered indicative of acquired
LQTS and risk for Tdp. QTc should be measured on 12-lead
EKG using standard equipment in a consistent manner for a
given patient.
A normal QT at baseline does not preclude excessive QT
prolongation and even development of Tdpwhen exposed to a
QT-prolonging drug.18 In the absence of marked QT prolon-
gation, Tdp risk could be explained by QT dispersion.17 QT
dispersion, defined as the inter-lead variation of QT duration
in a surface EKG. QT dispersion is calculated from the differ-
ence between the maximum and the minimum QTc in pre-
cordial leads. Values greater than 80 ms are considered
abnormally prolonged.
Other EKG features which may be associated with
increased risk of Tdp include interval from peak to the end of
the T wave, presence of T-wave alternans (change in ampli-
tude or polarity of T wave on alternating beats) and “TeU
waves”.19 Clinically, the EAD risk correlates well with the
presence of T wave humps, T-U waves or bifid T waves that
often precede the development of Tdp.20 However, exagger-
ated QT interval prolongation with T-U distortion after a
pause should be considered a strong marker of risk for Tdp.4.1. Dofetilide-induced Tdp
Among class III antiarrhythmics, sotalol and dofetilide are
associated with higher risk of Tdp than amiodarone despite
the fact that all of these agents can cause QT prolongation and
bradycardia. It has been suggested that dofetilide can induce
Tdp by multiple mechanisms including prolongation of
repolarization interval, slowing of heart rate, and increasing
repolarization heterogeneities in the ventricular myocardium
(manifested by increased QT dispersion in surface ECG).
However, for patients with congestion and reduced left ven-
tricular systolic function, changes in QT dispersion following
treatment with dofetilide do not predict cardiac mortality.21
Dofetilide exhibits reverse use dependence, which means
the duration of the action potential increases at slow heart
rates, increasing the risk for EADs and, therefore, Tdp. As
discussed earlier higher risk of Tdp is seen in patients who
have factors (Table 1) which cause prolonged QT interval and
or which facilitate formation of EAD. Torp-Pedersen et al
studied the risk factors of Tdp in patients with left ventricular
systolic dysfunction either due to heart failure (HF) or recent
myocardial infarction (MI) treated with dofetilide. They
concluded that severity of HF (Class III or IV, odd ratio e 3.9),
female gender (Odds ratio e 3.2), and baseline QTc duration
pose higher risk of early Tdp when treated with dofetilide.22
It has been proposed that women have a reduced cardiac
‘repolarization reserve’ resulting in a longer baseline-
corrected QT interval possibly due to influence of estrogen.23
This is supported by the higher risk of cardiac events in pre-
pubertal boys and higher in women during adulthood.24 Data
from the International LQTS Registry are consistent with this
hormonal theory.
In studies of patients with supraventricular arrhythmias,
ventricular tachycardia occurred in 2.0% and Tdp was seen in
0.8% of the patients.25 In The Danish Investigations of
Arrhythmia and Mortality on Dofetilide (DIAMOND) studies,22
themajority of Tdp and cardiac arrest occurredwithin the first
three days when the patient was in a monitored hospital
setting. Before 1994, Dofetilide dosing was not adjusted for
renal dysfunction and clinical trials used doses upto 750 mg.
This led to higher Tdp rates (upto 4.8%). DIAMOND studies
Do not start if 
Do not start if 
Do not start if Considering Dofetilide for atrial fibrillation, 
Hospitalize for continuous telemonitoring
Get Baseline EKG for QT (QTc) interval,
Serum Creatinine Clearance (Cr Cl), and 
serum electrolyte levels
Baseline QTc Cr Cl
Baseline QTc
>440msec
CrCl< 20ml/min
Dose: As per Cr Cl.
Cr Cl >60ml/min- 500 mcg bid
Cr Cl:40-60 ml/min- 250mcg bid
Cr Cl >20-40 ml/min- 125 mcg bid
2-3 hours after first dose or dose adjustment
Repeat 12 lead EKG 
Continue dosing
If QTc increase is <15% of baseline
Or <500 msec*
Adjust Dose 
If increase in QTc is >15% or >500 msec*
If 1st Dose was
500 mcg bid change to 250 mcg bid
250mcg bid change to 125 mcg bid
125 mcg bid change to 125 mcg once daily 
Discontinue
If QTc prolongation >25% or >550 msec
after 1st dose, and  
If is QTc >500 msec* after second dose.
* Or 550 msec when baseline ventricular conduction abnormalities are present
Check
Magnesium (Mg) and Potassium (K)
-If Mg <2.0 mg/dL, K+ <4.0mmol/ml;
may consider repleting 
Obese
(actual body weight >40% of 
Ideal body weight) Paroxysmal atrial fibrillation
Hypomagensemia:
Magnesium level is <1.5 mg/dL
Hypokalemia
Potassium Level is <3.5 mmol/L
Replete to keep 
Potassium Level is >4.0 mmol/L
Replete to keep 
Magnesium Level is >2.0 mg/dL
Fig. 4 e Algorithm for starting dofetilide in a patient with atrial fibrillation.
i n d i a n h e a r t j o u rn a l 6 6 ( 2 0 1 4 ) 6 4 0e6 4 8 645used 500 mg oral twice/day dose and showed a decreased Tdp
rate of 1.7%. The incidence of Tdp was 3.3% in the congestive
heart failure patients and 0.9% in the patients with a recent
myocardial infarction, with respectively 76% and 57% occur-
ring in the first 3 days of initiation of therapy. On the review of
published literature in pubmed we estimated a Tdp rate of
2.4% (89/3719) and 7 case reports with a sudden death rate of
0.05% (2/3719) amongst patients who were prescribed dofeti-
lide (Table 3).
4.2. Prevention strategies
Prevention of adverse reactions involves appropriate patient
selection and proper monitoring. In the absence of any other
contraindication (Tables 1 and 2) dofetilide should be initiated
in a hospital setting with continuous cardiac monitoring for
the first 3 days, or for a minimum of 12 h after cardioversion,
whichever is later. Cardioversion of atrial fibrillation is known
to increase the risk of QT prolongation.17 This is due to the fact
that dofetilide induces more QT prolongation after rhythm
conversion than during rapid atrial fibrillation. In the setting
of acute myocardial infarction and atrial fibrillation, myocar-
dial ischemia does not affect Dofetilide induced Tdp. Howev-
er, a case of Tdp in the setting of MI in an elderly patient has
been reported.26 Based on observations made in SAFIRE-D27
and DIAMOND studies an algorithm for the initiation,monitoring and dose adjustments for patients was developed
by the manufacturer of dofetilide (Pfizer). It should be avoided
in patients with congestive HF requiring aggressive diuresis as
diuretics may cause hypokalemia induced EAD and Tdp.
Similarly, patients with left ventricular hypertrophy have
higher chances of developing EAD and greater degree of QT
dispersion or heterogeneous ventricular myocardial
repolarization.
Dofetilide should not be used with any other antiar-
rhythmic agents. It should be only started after 3 half lives of
other agent have passed. Due to unpredictable half-life of
amiodarone, it should only be started after 3 months or when
serum amiodarone level falls below 0.3 mg/ml.28 However,
dofetilide has been used in patients after discontinuing
Amiodarone for 4e6 weeks without any adverse effects.29
It is recommended that serum creatinine should be
checked every three months in patients who are using Dofe-
tilide.28 Subsequent administration of drugs with potential to
cause QT prolongation should be avoided in the patients with
prior history of drug-induced severe QT prolongation and Tdp.
As discussed earlier, women with any other risk factors
(Table 1) are at particularly high risk for developing
arrhythmia from antiarrhythmics, and should be avoided.
Patients with history of sustained ventricular tachyarrhyth-
mias should not be started on such agents.14 In obese patients,
dofetilide dosing recommendation is not clear but based on
i n d i a n h e a r t j o u r n a l 6 6 ( 2 0 1 4 ) 6 4 0e6 4 8646data from studies we recommend that it should be avoided in
patients with actual body weight exceeding 40% above ideal
body weight.30 We propose a more practical algorithm (Fig. 4)
for dofetilide dosing and monitoring which includes recom-
mendations by the manufacturer, SAFIRE-D and DIAMOND
studies, and our suggestions.5. Management of dofetilide induced QT
prolongation and Tdp
QT prolongation should lead to prompt withdrawal of the
offending drug. An external defibrillator should be made
available. Careful assessment of potentially aggravating
drugedrug interactions, bradyarrhythmias, or electrolyte ab-
normalities should be done. We suggest that prophylactic
magnesium in cases of severe QT prolongation (>500ms) after
the first dose might decrease the risk of ventricular arrhyth-
mias. Intravenous magnesium reduces the QTc interval of
patients receiving ibutilide and oralmagnesium lactate lowers
the QTc interval of patients receiving sotalol or dofetilide.31
Treatment of dofetilide induced ventricular tachycardia/
Tdp is not well described. It should be managed as Tdp from
any other cause. Immediate direct-current cardioversion
should be performed for patients with Tdp that does not
terminate spontaneously or that degenerates into ventricular
fibrillation. Even in the absence of hypomagnesemia, intra-
venousmagnesium sulfate should be administered in patients
with frequent ventricular arrhythmia and Tdp. Magnesium
sulfate 2.0 g can be infused intravenously, and if episodes of
Tdp persist, it might be necessary to repeat infusions of
magnesium sulfate.32 Repletion of potassium to maintain the
serum levels of 4.5 mmol/l to 5 mmol/l may also be consid-
ered, although there is little evidence to support this prac-
tice.32 If patient’s heart rate is on the lower side (<85 beats per
minute), isoproterenol or temporary pacing may be used to
increase heart rate and hence, shorten QT interval. However,
itmay not be helpful in every patient as it has been shown that
beta-adrenergic stimulation could be arrhythmogenic in
conditions of acquired LQTS when subclinical IKs dysfunction
is present and heart rate is not fully increased.16 Clinically
such distinction between patients cannot be made and we
recommend using isoproterenol in Tdp patients if their heart
rate is slow.6. Conclusion
Dofetilide is an effective and relatively safe AAD for conver-
sion to sinus rhythm and maintenance of it in patients with
atrial fibrillation. However, caution should be exercised in
selecting appropriate patients before starting it as majority of
the dofetilide induced proarrhythmic events happen in the
presence of another offending factor. Risk factors for dofeti-
lide associated Tdp include older age, female sex, heart dis-
ease, electrolyte disorders (especially hypokalemia and
hypomagnesemia), renal or hepatic dysfunction, bradycardia
or rhythms with long pauses, treatment with other QT-pro-
longing drugs, and genetic predisposition. The risk-benefit
ratio should be assessed for each individual to determinewhether the potential therapeutic benefit of the drug out-
weighs the risk for Tdp. After initiation of a drug associated
with Tdp, ECG signs indicative of arrhythmia risk include
an increase in QTc from baseline of more than 50 ms, marked
QTc interval prolongation >500 ms, TeU wave distortion
that becomes more exaggerated in the beat after a pause,
visible (macroscopic) T-wave alternans, new-onset ventricu-
lar ectopy, couplets and non sustained polymorphic ventric-
ular tachycardia initiated in the beat after a pause. Monitoring
of QT intervals before and after drug administration should be
done in a consistent method utilizing the same recording
device, ECG lead, measurement tool (automated or manual),
and heart rate correction formula. Recommended actions
when ECG signs of impending Tdp develop should include
stopping further doses of the offending drug, replacing po-
tassium, administering magnesium, temporary pacing can be
considered to prevent bradycardia (heart rate <75 beats per
minute) and long pauses, and transfer the patient to a coro-
nary care unit with continuous telemonitoring with an im-
mediate defibrillation option is available.Disclosure
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